MetaVia Inc.
MTVA
Rang in Aktien
#32904
Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a... Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a clinical-stage biotechnology company with a core focus on discovering and commercializing novel pharmaceutical solutions for cardiometabolic disorders. Its leading investigational drug, DA-1241, a unique G-Protein-Coupled Receptor 119 agonist, is currently undergoing Phase 2a clinical trials for metabolic dysfunction-associated steatohepatitis (MASH). This follows the successful completion of Phase 1 trials for type 2 diabetes mellitus (T2DM), and the compound holds promise for use as both a standalone therapy and in combination treatments. Another significant asset, DA-1726, an innovative oxyntomodulin analogue that functions as a dual agonist for GLP-1 and glucagon receptors, is presently in preclinical development specifically for treating obesity. MetaVia's broader therapeutic pipeline also includes ANA001, a distinct oral niclosamide formulation intended for moderate COVID-19 patients; NB-01, designed to address painful diabetic neuropathy; NB-02, targeting cognitive impairment; and Gemcabene, for the management of dyslipidemia. The company engages in strategic partnerships, notably a licensing agreement with Pfizer Inc. for the research, development, manufacturing, and commercialization of Gemcabene. Additionally, a joint research collaboration with Dong-A ST and ImmunoForge supports the advancement of DA-1726. The entity adopted its current name, MetaVia Inc., in November 2024, transitioning from its former identity as NeuroBo Pharmaceuticals, Inc.
Aktienkurs
$1.28
Zuletzt synchronisiert: 2026-10-20
Marktkapitalisierung
$8.43M
Veränderung (1 Tag)
4.07%
Veränderung (1 Jahr)
-21.47%
Land
US
Handel MetaVia Inc. (MTVA)
Kategorie
Healthcare
Anzahl der ausstehenden Aktien von MetaVia Inc. (MTVA)
Anzahl der ausstehenden Aktien zum June 2026: 5.93B
Laut den neuesten Finanzberichten und dem Aktienkurs von MetaVia Inc. beträgt die aktuelle Anzahl der ausstehenden Aktien 5.93B. Am Ende von December 2023 hatte das Unternehmen 5.07M ausstehende Aktien. Die Anzahl der ausstehenden Aktien wird normalerweise durch Aktiensplits und Aktienrückkäufe beeinflusst.
Verlauf der ausstehenden Aktien von MetaVia Inc. (MTVA) von 2014 bis 2026
Ausstehende Aktien am Ende jedes Jahres
| Jahr | Ausstehende Aktien | ändert |
|---|---|---|
| 2026 (TTM) | 5.93B | 7,547.03% |
| 2024 | 77.57M | 1,430.30% |
| 2023 | 5.07M | 1,475.68% |
| 2022 | 321.70K | 233.61% |
| 2021 | 96.43K | 42.71% |
| 2020 | 67.57K | 221.77% |
| 2019 | 21.00K | 18.56% |
| 2018 | 17.71K | 28.37% |
| 2017 | 13.80K | 78.15% |
| 2016 | 7.75K | 9.58% |
| 2015 | 7.07K | 0.00% |
| 2014 | 7.07K | 0.00% |
Ausstehende Aktien bei ähnlichen Unternehmen oder Wettbewerbern
| Unternehmen | Ausstehende Aktien | Unterschied | Land |
|---|---|---|---|
| 253.90M | -95.72% |
US
|
|
| 396.00M | -93.32% |
US
|
|
| 478.91M | -91.93% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -98.95% |
NL
|
